Early intervention in bipolar disorder, part II: Therapeutics

Early Intervention in Psychiatry

Volumn 2, Issue 3, 2008, Pages 136-146

  Salvadore, Giacomo ^a   Drevets, Wayne C ^a   Henter, Ioline D ^a   Zarate, Carlos A ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bipolar disorder; Early intervention; Lithium; Neurotrophic effect; Valproate

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCOSE SYNTHASE KINASE 3; GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; LITHIUM SALT; MEMANTINE; MOOD STABILIZER; OLANZAPINE; PLACEBO; PROTEIN BCL 2; QUETIAPINE; REGULATOR PROTEIN; RILUZOLE; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS VECTOR;

AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; BIPOLAR DISORDER; BRAIN ISCHEMIA; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COGNITIVE THERAPY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; EARLY INTERVENTION; ENZYME INHIBITION; GENE THERAPY; HIGH RISK PATIENT; HUMAN; MAJOR DEPRESSION; METABOLIC DISORDER; MOOD DISORDER; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSYCHOEDUCATION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; WEIGHT GAIN;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN; EARLY DIAGNOSIS; HUMANS; LITHIUM COMPOUNDS; RILUZOLE; TRIAZINES; VALPROIC ACID;

EID: 65249092613     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2008.00072.x     Document Type: Review

References (117)

1. McGlashan TH, Zipursky R, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-9.
2. McGorry P, Yung A, Phillips L et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-8.
3. Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: Targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006; 59: 1006-20.
4. Berger G, Dell'Olio M, Amminger P et al. Neuroprotection in emerging psychotic disorders. Early Interv Psychiatry 2007; 1: 114-27.
5. Duffy A, Alda M, Crawford L, Milin R, Grof P. The early manifestations of bipolar disorder: A longitudinal prospective study of the offspring of bipolar parents. Bipolar Disord 2007; 9: 828-38.
6. Hillegers MH, Reichart CG, Wals M, Verhulst FC, Ormel J, Nolen WA. Five-year prospective outcome of psychopathology in the adolescent offspring of bipolar parents. Bipolar Disord 2005; 7: 344-50.
7. Baum AE, Akula N, Cabanero M et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008; 13: 197-207.
8. Sklar P, Smoller JW, Fan J et al. Whole-genome association study of bipolar disorder. Mol Psychiatry 2008; 13: 558-69.
9. Scott J, Meyer TD. Editorial: Prospects for early intervention in bipolar disorders. Early Interv Psychiatry 2007; 1: 111-3.
10. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4: 183-94.
11. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 2001; 11: 240-9.
12. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
13. Young LT. Neuroprotective effects of antidepressant and mood stabilizing drugs. J Psychiatry Neurosci 2002; 27: 8-9.
14. Chang K, Steiner H, Dienes K, Adleman N, Ketter T. Bipolar offspring: A window into bipolar disorder evolution. Biol Psychiatry 2003; 53: 945-51.
15. Lambert M, Conus PO, Schimmelmann BG et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: Results of an open retrospective medical record study. Pharmacopsychiatry 2005; 38: 206-13.
16. Saxena K, Howe M, Simeonova D, Steiner H, Chang K. Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder. J Child Adolesc Psychopharmacol 2006; 16: 252-9.
17. Findling RL, Frazier TW, Youngstrom EA et al. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. J Clin Psychiatry 2007; 68: 781-8.
18. Geller B, Cooper TB, Zimerman B et al. Lithium for prepubertal depressed children with family history predictors of future bipolarity: A double-blind, placebo-controlled study. J Affect Disord 1998; 51: 165-75.
19. Baldessarini RJ, Tondo L, Hennen J, Viguera AC. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002; 10: 59-75.
20. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 2007; 68: 789-95.
21. Strakowski SM, Keck P, McElroy SL et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry 1998; 55: 49-55.
22. Tohen M, Hennen J, Zarate CA et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000; 157: 220-8.
23. Costa C, Martella G, Picconi B et al. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 2006; 37: 1319-26.
24. Manji HK, Moore GJ, Chen G. Bipolar disorder: Leads from the molecular and cellular mechanisms of action of mood stabilizers. Br J Psychiatry Suppl 2001; 41: S107-19.
25. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281: 1322-6.
26. Bruckheimer EM, Cho SH, Sarkiss M, Hermann J, McDonnell TJ. The Bcl-2 gene family and apoptosis. Adv Biochem Eng Biotechnol 1998; 62: 75-105.
27. Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Annu Rev Neurosci 1997; 20: 245-67.
28. Chen G, Zeng WZ, Yuan PX et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-82.
29. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: Therapeutic implications. J Clin Psychiatry 1999; 60: 27-39; discussion 40-1, 113-6.
30. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000; 5: 578-93.
31. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000; 48: 766-77.
32. Manji HK, Moore GJ, Chen G. Lithium at 50: Have the neuroprotective effects of this unique cation been overlooked. Biol Psychiatry 1999; 46: 929-40.
33. Manji HK, Moore GJ, Chen G. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: A role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 2000; 61 (Suppl. 9): 82-96.
34. Li H, Yuan J. Deciphering the pathways of life and death. Curr Opin Cell Biol 1999; 11: 261-6.
35. Sadoul R. Bcl-2 family members in the development and degenerative pathologies of the nervous system. Cell Death Differ 1998; 5: 805-15.
36. Bonfanti L, Strettoi E, Chierzi S et al. Protection of retinal ganglion cells from natural and axotomy-induced cell death in neonatal transgenic mice overexpressing bcl-2. J Neurosci 1996; 16: 4186-94.
37. Chen DF, Schneider GE, Martinou JC, Tonegawa S. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 1997; 385: 434-9.
38. Lawrence MS, Ho DY, Sun GH, Steinberg GK, Sapolsky RM. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. J Neurosci 1996; 16: 486-96.
39. Raghupathi R, Fernandez SC, Murai H et al. BCL-2 overexpression attenuates cortical cell loss after traumatic brain injury in transgenic mice. J Cereb Blood Flow Metab 1998; 18: 1259-69.
40. Yang L, Matthews RT, Schulz JB et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 1998; 18: 8145-52.
41. Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277: 559-62.
42. Gould TD, Manji HK. Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005; 30: 1223-37.
43. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-9.
44. Bachmann RF, Schloesser RJ, Gould TD, Manji HK. Mood stabilizers target cellular plasticity and resilience cascades: Implications for the development of novel therapeutics. Mol Neurobiol 2005; 32: 173-202.
45. Grimes AC, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3beta and facilitated by lithium. J Neurochem 2001; 78: 1-15.
46. Gurvich N, Klein PS. Lithium and valproic acid: Parallels and contrasts in diverse signaling contexts. Pharmacol Ther 2002; 96: 45-66.
47. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997; 272: 19547-53.
48. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003; 423: 435-9.
49. Chuang DM, Priller J. Potential use of lithium in neurodegenerative disorders. In: Bauer M, Grof P, Muller-Oerlinghausen B, eds. Lithium in Neuropsychiatry the Comprehensive Guide. Abingdon; Oxon: Informa UK Ltd, 2006; 381-98.
50. Liang M-H, Chuang DM. Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem 2007; 282: 3904-17.
51. Ren M, Senatorov VV, Chen RW, Chuang DM. Post-insult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci USA 2003; 100: 6210-5.
52. Xu J, Culman J, Blume A, Brecht S, Gohlke P. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 2003; 34: 1287-92.
53. Noble W, Planel E, Zehr C et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005; 102: 6990-5.
54. Rockenstein E, Torrance M, Adame A et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007; 27: 1981-91.
55. de Ferrari GV, Chacon MA, Barria MI et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 2003; 8: 195-208.
56. Moore GJ, Bebchuk JM, Hasanat K et al. Lithium increases N-acetyl-aspartate in the human brain: In vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000; 48: 1-8.
57. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-2.
58. Drevets WC, Price JL, Simpson JRJ et al. Subguenal prefrontal cortex abnormalities in mood disorders. Nature 1997; 386: 824-7.
59. Bearden CE, Thompson PM, Dalwani M et al. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 2007; 62: 7-16.
60. Chang K, Barnea-Goraly N, Karchemskiy A et al. Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Biol Psychiatry 2005; 58: 197-203.
61. Sassi RB, Brambilla P, Hatch JP et al. Reduced left anterior cingulate volumes in untreated bipolar patients. Biol Psychiatry 2004; 56: 467-75.
62. Sassi RB, Nicoletti M, Brambilla P et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002; 329: 243-5.
63. Schloesser RJ, Chen G, Manji HK. Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder. Int Rev Neurobiol 2007; 77: 143-78.
64. Chen G, Manji HK. The extracellular signal-regulated kinase pathway: An emerging promising target for mood stabilizers. Curr Opin Psychiatry 2006; 19: 313-23.
65. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001; 276: 31674-83.
66. Wang JF, Azzam JE, Young LT. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 2003; 116: 485-9.
67. Sinn DI, Kim SJ, Chu K et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Disord 2007; 26: 464-72.
68. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: Involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002; 80: 589-97.
69. Chen PS, Peng GS, Li G et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11: 1116-25.
70. Martinowich K, Manji HK, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007; 10: 1089-93.
71. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 2003; 18: 73-9.
72. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 2005; 9: 153-68.
73. Paul IA, Skolnick P. Glutamate and depression: Clinical and preclinical studies. Ann N Y Acad Sci 2003; 1003: 250-72.
74. Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implement glutamate neurotransmission in mood disorders. Ann N Y Acad Sci 2003; 1003: 292-308.
75. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003; 23: 484-95.
76. Shuaib A, Mahmood RH, Wishart T et al. Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study. Brain Res 1995; 702: 199-206.
77. McGeer EG, Zhu SG. Lamotrigine protects against kainate but not ibotentate lesions in rat striatum. Neurosci Lett 1990; 112: 348-51.
78. Di Daniel E, Mudge AW, Maycox PR. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord 2005; 7: 33-41.
79. Du J, Suzuki K, Wei Y et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007; 32: 793-802.
80. Zarate CA Jr, Payne JL, Quiroz J et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161: 171-4.
81. Zarate CA Jr, Quiroz JA, Singh JB et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57: 430-2.
82. Sanacora G, Kendell SF, Levin Y et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61: 822-5.
83. Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the glutamatergic system: Implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002; 36: 35-83.
84. Katoh-Semba R, Asano T, Ueda H et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J 2002; 16: 1328-30.
85. Kalra S, Chashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998; 9: 1757-61.
86. Kalra S, Tai P, Genge A, Arnold DL. Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. J Neurol 2006; 253: 1060-3.
87. Mathew SJ, Price RB, Mao X et al. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry 2008; 63: 891-8.
88. Zarate CA, Singh J, Quiroz J et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163: 153-5.
89. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007; 30: 136-44.
90. Zarate CA Jr, Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-64.
91. Maeng S, Zarate CA Jr, Du J et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-52.
92. Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+ -induced apoptosis. Eur J Neurosci 2003; 17: 1563-70.
93. Wei J, Bai O, Richardson JS, Mousseau DD, Li XM. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res 2003; 73: 365-8.
94. Yulug B, Yildiz A, Hudaoglu O, Kilic E, Cam E, Schabitz WR. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain Res Bull 2006; 71: 296-300.
95. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003; 71: 127-31.
96. Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004; 1010: 81-6.
97. DelBello MP, Cecil KM, Adler CM, Daniels JP, Strakowski SM. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: A proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2006; 31: 1264-73.
98. Tohen M, Kryzhanovskaya L, Carlson G et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164: 1547-56.
99. McClellan JM. Olanzapine and pediatric bipolar disorder: Evidence for efficacy and safety concerns. Am J Psychiatry 2007; 164: 1462-4.
100. Bian Q, Kato T, Monji A et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 42-8.
101. Yulug B, Yildiz A, Guzel O, Kilic E, Schabitz WR, Kilic E. Risperidone attenuates brain damage after focal cerebral ischemia in vivo. Brain Res Bull 2006; 69: 656-9.
102. Xu H, Qing H, Lu RB et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002; 321: 65-8.
103. Post RM, Leverich GS, Xing G, Weiss RB. Developmental vulnerabilities to the onset and course of bipolar disorder. Dev Psychopathol 2001; 13: 581-98.
104. Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402-7.
105. Frank E, Kupfer DJ, Thase ME et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005; 62: 996-1004.
106. Lam D. What can we conclude from studies on psychotherapy in bipolar disorder? Invited commentary on... Cognitive-behavioural therapy for severe and recurrent bipolar disorders. Br J Psychiatry 2006; 188: 321-2.
107. Miklowitz DJ, Otto MW, Frank E et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry 2007; 164: 1340-7.
108. Scott J, Paykel ES, Morriss R et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders. Br J Psychiatry 2006; 188: 313-20.
109. Yukimasa T, Yoshimura R, Tamagawa A et al. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Phamarcopsychiatry 2006; 39: 52-9.
110. Zanardini R, Gazzoli A, Ventriglia M et al. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord 2006; 91: 83-6.
111. Correll CU, Penzer JB, Frederickson AM et al. Differentiation in the preonset phases of schizophrenia and mood disorders: Evidence in support of a bipolar mania prodrome. Schizophr Bull 2007; 33: 703-14.
112. Adli M, Hollinde DL, Stamm T et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry 2007; 62: 1295-302.
113. Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G. Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 500-4.
114. Coryell W, Scheftner W, Keller MB, Endicott J, Maser J, Klerman GL. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993; 150: 720-7.
115. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II patients. Arch Gen Psychiatry 2003; 60: 261-9.
116. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-7.
117. Moore PB, Schepherd DJ, Eccleston D et al. Cerebral white matter lesions in bipolar affective disorder: Relationship to outcome. Br J Psychiatry 2001; 178: 172-6.